Retatrutide: what does this trial say about weight?
The summary describes a phase 2 trial in adults with obesity.
What did they want to find out?
They wanted to know what weight changes occurred with retatrutide.
What does this example say?
The example says people in the group lost weight on average.
What does this mean for you?
The summary describes one stage of research. It does not guarantee results for someone considering the compound.
What we still do not know
This example is unverified. It is not an up-to-date review of the compound's development or its long-term effects.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: retatrutide, a triple agonist, in obesity
New England Journal of Medicine · 2023
How it was studied
Phase 2 randomized trial. n = 338 adults.
Original example finding
Up to 24.2% mean weight reduction at 48 weeks, the largest reported in the context of the supplied summary.
Original example limitations
Unverified profile. Summarizes phase 2 only; it is not an update on long-term safety or effects on heart rate.
Terms explained
- Phase 2
- A stage of testing in people. It does not mean everything about the compound is already known.
This link opens PubMed's search site, not a checked paper for this summary.
Open PubMed (reference unverified)